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Endovascular Treatment of Peripheral Artery
Disease (PAD): So Old Yet So Far from Evidence!P. Cao*, P. De RangoDivision of Vascular and Endovascular Surgery, University of Perugia, Ospedale S. Maria della Misericordia, Piazza Menghini
1, 06100 Perugia, ItalyDespite a persisting debate, progress has been rapid and
clinical efficacy of endovascular approach for treatment of
aortic, coronary, and carotid disease has been demon-
strated, whereas proof of clinical benefit of this approach
has been more elusive for Peripheral Arteries Disease (PAD).
This scenario would not have been expected 40 years ago
when the endovascular approach was first applied. Even
with the earliest technology, it appeared that the large
clinical need in patients with PAD and the safety of endo-
luminal approach would have driven its clinical adoption in
PAD much faster than in other vascular territories. A
number of issues have proven to be unsolved in the clinical
reality, including patient selection, proof of efficacy,
hurdles in conducting randomized clinical trials (RCTs). For
some reasons, research in this field has not been
adequately funded and many studies are underpowered,
therefore the optimal treatment strategy for PAD is still
debated. Even the most updated literature involves small
numbers of patients and does not operate with uniformly
definite endpoints, rendering a direct comparison among
studies difficult and generalization of results questionable.
The RCTs comparing angioplasty to supervised exercise
published in the nineties, the Edinburgh trial1 and the Oxford
trial2 included very few patients (64 patients in Edinburgh’s,
56 patients in Oxford’s) and provided inconclusive and
disparate results. The recently published MIMIC3 study
investigating adjuvant angioplasty in patients with mild to
moderate intermittent claudication in 2 separate RCTs for
femoro-popliteal and aorto-iliac disease attempted to
provide a larger sample size than the previous RCTs. The* Corresponding author. Tel.: þ39 075 578 6436; fax: þ39 075 578
6435.
E-mail address: pcao@unipg.it (P. Cao).
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doi:10.1016/j.ejvs.2009.03.005MIMIC message is that PTA confers adjuvant benefit over
supervised exercise and Best Medical Treatment (BMT) in
terms of walking distances at 24 months after PTA with 38%
increase (95% CI 1e90; pZ 0.04) in the femoro-popliteal
trial and 78% increase (95% CI 0e216; pZ 0.05) in the aorto-
iliac trial. Unfortunately, of the intended recruitment of 340
patients in both trials, only 127 patients were actually
included (93 patients in the femoro-popliteal trial and 34
patients in the aorto-iliac trial). In a significant number of
patients randomized to angioplasty, the procedure was
never attempted because symptoms improved spontane-
ously, raising the doubt that with a longer delay other
patients would not have needed any invasive treatment.
Furthermore, follow-up of 15% of patients was not available
because they were unable to perform a treadmill test due to
severe comorbidities or other conditions such as unstable
angina or non-vascular reasons that probably precluded
them from any active lifestyle.
Given the small power of the difference in outcomes,
the unavoidable risk of procedure-related complications
and the adjunctive cost of the interventions, the suggestion
that iliac or femoral angioplasty is beneficial in patients
with moderate to mild claudication is still an open issue
especially when severe comorbidities are present.
What about more severe PAD with Critical Limb Ischemia
(CLI)? The balance between bypass surgery (more risky but
more effective and durable) and a spectrum of modern
percutaneous procedures (less invasive but less applicable
and durable) has been evaluated by the BASIL trial
comparing bypass surgery versus angioplasty in severe
ischemia of the leg.4 The trial continued for 5.5 years with
452 patients randomized and showed no substantial
differences and broadly similar outcomes in terms of
amputation-free survival between bypass surgery or balloond by Elsevier Ltd. All rights reserved.
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benefit beyond 2 years from randomization was suggested
in favor of surgery by post hoc analysis.
Are the limitations of the other studies, such as small
patient numbers, poorly defined inclusion criteria
(different degrees of limb ischemia, aorto-iliac and infra-
inguinal lesions), short or incomplete follow-up, solved in
the BASIL trial?
Unfortunately, only 48% of patients had been followed at
3 years and 22% at 4 years, producing small numbers for
long-term analysis and low late events rates. Furthermore
the survival ranging 50e60% at 4 years appears high for
patients with CLI and raises doubt about patient selection.
In addition, the unusually high rate of wound infections
(23%) in the surgical arm makes the results of this multi-
centric trial difficult to generalize.
Therefore, it is not surprising that today most informa-
tion on PAD relies on a number of small or non-randomized
series unable to provide strong evidence on disparate
revascularization strategies. These range from the less
expensive simple percutaneous balloon transluminal (PTA)
or subintimal angioplasty to the more costly multiple stent
technologies, cryoplasty, atherectomy, and remote endar-
terectomy in which commercially driven interests may play
an important role.
As a consequence of such heterogeneity, studies
assessing endovascular treatment of PAD do not operate
with uniform terminology and endpoint definitions. The
new multidisciplinary team (DEFINE) recently provided new
reporting standards for baseline and endpoint definitions
compatible with the peripheral revascularization tech-
niques for lower limb ischemia.5 New terminology coined in
coronary trials has been suggested to replace the tradi-
tional one. Accordingly, rates of ‘‘repeated target lesion
revascularization (TLR)’’ and absence of ‘‘binary reste-
nosis’’ should replace the term ‘‘patency’’ (primary, assis-
ted, secondary). Is this appropriate? Or should we favour
the attainment of symptoms improvement and quality of
life? In addition, how can the endovascular results be
compared to those of bypass in terms of TLR?
It is evident that traditional standards are still useful.
PAD is a multilevel obstructive disease in which outcome of
treatment is affected by a multitude of factors broader
than and dissimilar from those operating in coronary
disease.
Much uncertainty remains with regard to the best
approach for treatment of PAD despite the variety of
percutaneous therapeutic options. Hopefully the results of
ongoing and future trials will help to address these issues.
In the meantime, the existing comprehensive guidelines
and updated standards, as Rutherford/SVS/ISCVS, SIR,6,7
ACC/AHA recommendations8 and Trans-Atlantic Inter-
Society Consensus II (TASC) document are available.9
Despite some redundancies or confusing definitions, these
can provide guidance for the management and treatment
options.
However, significant challenges remain when
comparing endovascular versus traditional therapy for
PAD. The question to be answered is not only to what
extent less efficacy and durability can be accepted for
less invasive treatment, but also if any invasive therapy
should be pursued in patients with PAD given their poorprognosis, high procedural risk, and short lifespan
Consequently:
1. The bar to promote catheter-based approaches in
patients with mild to moderate claudication should be
high, given the proven safety and efficacy of supervised
exercise and best medical treatment.
2. The challenge is different for patients with CLI. The
demonstration of clinical benefit has been questioned in
the surgical procedures due to high morbidity and
mortality rates, but it will be even more difficult to show
therapeutic benefit of endovascular approaches. Efficacy
anddurabilityare reportedbutareonlyproven in selected
centers with high volume and elevated technical skills.
3. Although the goal of all endovascular procedures is the
correction of arterial lesions, trial designs are different
from that of coronary or carotid disease. Results and
terminology in coronary, carotid or aortic disease may
be misleading if directly transferred into PAD patients.
4. To select the appropriate treatment options in PAD we
need large trials reporting patency, limb salvage or
mortality, but also using surrogate endpoints as func-
tional improvement and quality of life. Short-term effi-
cacymay be acceptable, given the short life expectancy.
5. Finally, most of the new devices are increasingly
expensive and there is no reliable documentation on
their cost-effectiveness. Adherence to Reporting Stan-
dards and International Guidelines is a key that should
not be omitted in peer publications.
In conclusion, the challenges of therapy for PAD patients
remain formidable. Regrettably after forty years of efforts,
endovascular treatment is still far from gaining proof of
efficacy and applicability. There are objective difficulties in
conducting level I studies in patients with a multilevel
disease in which outcome of treatment is affected by
multiple, clinical and morphological factors.
Due to the unfavorable and variable natural history of
PAD with respect to other arterial locations of atheroscle-
rosis, we cannot expect any revolutionary change in the
outcomes. In addition, due to the multiple comorbidities,
different patterns of risk factors and stages of the disease
treatment cannot be standardized but need to be tailored
to the individual patient. Considering these limitations, we
should perhaps favour clinical trials with functional
improvement and quality of life as primary endpoints. We
should not let enthusiasm for the new technologies blind
ourselves in reality, but the limited evidence showing effi-
cacy of the endovascular treatment in PAD should
encourage and not disprove the promotion of larger
controlled studies in this challenging field.
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